Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)

Abstract Even though pulmonary arterial hypertension (PAH) remains an incurable disease, the combination of PAH‐specific therapies allowed treatment strategies to evolve from symptom‐based ones to others that aim to move patients to low‐risk conditions. Endothelin‐1 (ET‐1) receptor antagonists emerg...

Full description

Bibliographic Details

Published in:	Pulmonary Circulation
Main Authors:	Abdullah M. Aldalaan, Sarfraz A. Saleemi, Ihab Weheba, Abeer Abdelsayed, Maha M. Aleid, Fatima Alzubi, Hamdeia Zaytoun, Nadeen Alharbi
Format:	Article
Language:	English
Published:	Wiley 2022-04-01
Subjects:	Bosentan efficacy Macitentan pulmonary arterial hypertension safety switch
Online Access:	https://doi.org/10.1002/pul2.12083